Quarterly Activities/Appendix 4C Cash Flow Report
Released
Released
Announcement PDF
ASX Announcement
Quarterly Cash Flow Statement & Operational Highlights
Highlights:
•
Registrational Phase 3 Clinical Trial Update – Indonesia’s Food and Drug
Authority Meeting and Clinical Trial Sites Onboarded
•
Phase 2 Clinical Trial receives additional approval allowing patients with Diabetic
Foot Infections further access to RECCE® 327 Topical Gel (R327G)
•
United States Army Medical Research Institute of Infectious Diseases (USAMRIID)
Cooperative Research & Development Agreement
•
A$15.8 million capital raising complete – all from existing shareholders
•
Non-Dilutive Financing via debt facility of up to ~A$30 million with Avenue Capital
Group
•
China Patent Accepted for RECCE® Anti-Infectives
•
Canadian Scientific Research & Experimental Development Rebate Received
SYDNEY Australia, 31 July 2025: Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (Recce or
the Company), a leading developer of a New Class of Synthetic Anti-infectives, today released its
Q4 FY2025 results and operational highlights.
Operational Highlights
Registrational Phase 3 Clinical Trial Update - Indonesia’s Food and Drug Authority
Meeting and Clinical Trial Sites Onboarded
During
the
quarter,
the
Company
held
successful meetings with Indonesia’s Food
and Drug Authority (Badan POM), with the
Company expanding Phase 3 clinical trial sites
across
Indonesia.
Recce’s
clinical
staff
onboarded additional hospitals and clinical trial
sites to maximise patient recruitment.
Recce Management and Clinical staff with
Indonesia’s Food and Drug Authority.
Phase 2 Clinical Trial Receives Additional Approval Allowing Patients with Diabetic Foot
Infections Further Access to RECCE® 327 Topical Gel (R327G)
The Company announced it has received Human Research Ethics Approval (HREC) approval to
allow Diabetic Foot Ulcer Infection patients further access to R327G under the same Phase 2
Clinical Trial protocol. With around 40% of those who get a diabetic foot ulcer having another ulcer
occurrence within the first year, the Company made further access available on ethical grounds,
while at the same time welcoming the opportunity of new patient data.
The use of R327G under this protocol follows positive results in a Phase 2 Acute Bacterial Skin
and Skin Structure Infections (ABSSSI) clinical trial (announced 17 February 2025), where R327G
demonstrated 86% of patients treated had a successful clinical response after 7-days of treatment
and >90% at 14 days treatment. These results were assessed under an FDA recognised
assessment method of Lipski Scale & Bates Jensen Wound Assessment Tool.
United States Army Medical Research Institute of Infectious Diseases (USAMRIID)
Cooperative Research & Development Agreement
The Company announced it has entered into a Cooperative Research and Development
Agreement (CRADA) with the United States Army Medical Research Institute of Infectious
Diseases (USAMRIID), with partnership and funding from the Defense Threat Reduction Agency.
This is the 2nd research agreement with the United States
Department of Defense (DoD) alongside a present Topical
Burn Wound program.
USAMRIID is the United States Army’s premier institution
and facility for defensive research into countermeasures
against biological warfare. The USAMRIID is the only
laboratory in the United States DoD equipped to safely study
highly
hazardous
pathogens
requiring
maximum
synthetic
anti-infective
containment at Biosafety Level 4.
USAMRIID
RECCE
®
is
testing
Recce’s
327 (R327) against a panel of biodefence
pathogens in USAMRIID’s established in vitro infection
James Graham (CEO), Dr John Prendergast
(Executive Chairman), Dr Alan Dunton
(Chief Medical Advisor & Non-Executive
Director) in Washington DC.
models. Upon successful testing, the next phase of evaluation may progress to small animal model
testing.
Following this agreement, Recce’s management team recently conducted meetings with key
United States DoD personnel and government officials in Washington DC in response to increasing
interest.
Canadian Scientific Research & Experimental Development Rebate Received
The Company announced an international cash receipt of US$175,122 (~A$271,987) from the
Canadian Government as part of its Scientific Research & Experimental Development (SR&ED)
Tax Incentive program. The funds represent the Canadian government’s 10% Research and
Development (R&D) rebate, which is in addition to the Australian government’s 43.5% R&D Tax
Incentive Program, from which the Company expects to receive later this calendar year.
China Patent Accepted for RECCE® Anti-Infectives
The Company announced the receipt of a Notice of Acceptance from the China National Intellectual
Property Administration for Patent Family 4 for Recce’s Anti-infectives, expiry 2041. This is the fifth
Family 4 patent, alongside Australia, Canada, Japan and Israel, with further Patent Cooperation
Treaty Country submissions in respective stages of review.
Financial Update
The Company ended the quarter with a cash balance of A$10.53 million. Net cash outflows from
operating activities were (A$10.81 million), with Research and Development (A$8.8 million) being
the largest item of expenditure supporting ongoing human clinical trials, and the advancement of
pre-clinical studies. Payments to related parties (Executive & Director fees) were (A$0.79 million).
A$15.8 million capital raising complete – all from existing shareholders
The Company raised A$15.8 million (before costs) with all funds raised coming from existing
shareholders. Proceeds will be applied to the following:
•
Phase 3 Diabetic Foot Infection (DFI) Registrational Topical Clinical Trial in Indonesia – the
catalyst for revenue in 2026;
•
Phase 3 Acute Bacterial Skin and Skin Structure Infections Registrational Topical Clinical
Trial in Australia;
•
Additional clinical activities, Investigational New Drug Application to the FDA and general
working capital.
Non-Dilutive Financing via Debt Facility with Avenue Capital Group
A debt facility of up to ~A$30.55 million (US$20.0 million) with ~A$11.49 million (US$7.5 million)
drawn and a further ~A$19 million (US$12.5 million) available subject to drawdown conditions was
secured from global investment firm Avenue Capital Group.
The facility provides non-dilutive growth capital to support Recce’s Phase 3 clinical trial activities
in Indonesia and Australia for the treatment of DFIs and ABSSSI, as well as broader
commercialisation efforts across the ASEAN region.
Looking Ahead
With a successful A$15.8 million capital raise, ~A$11.49 million non-dilutive funding plus the
Company retains its FY25 R&D rebate of ~A$8.5 million (expected November 2025) sees an
effective ~A$39.63 million cash runway.
Rule 4.7B
Appendix 4C
Quarterly cash flow report for entities
subject to Listing Rule 4.7B
Name of entity
Recce Pharmaceuticals Ltd
ABN
Quarter ended (“current quarter”)
73 124 849 065
June 2025
Consolidated statement of cash flows
Current quarter
1.
Cash flows from operating activities
1.1
Receipts from customers
1.2
Payments for
(a) research and development
(b) product manufacturing and operating
costs
(c) advertising and marketing
(d) leased assets
(e) staff costs
(f)
administration and corporate costs
Year to date (12
months)
-
-
(8,804,053)
(20,426,224)
-
-
(310,488)
(1,827,757)
-
-
(626,890)
(2,503,629)
(1,384,378)
(2,715,485)
-
-
1.3
Dividends received (see note 3)
1.4
Interest received
2,793
78,532
1.5
Interest and other costs of finance paid
(1,798)
(12,832)
1.6
Income taxes paid
-
-
1.7
Government grants and tax incentives
-
6,971,366
1.8
Other
313,638
472,861
1.9
Net cash from / (used in) operating
activities
(10,811,175)
(19,963,168)
2.
Cash flows from investing activities
2.1
Payments to acquire or for:
(a) entities
-
-
(b) businesses
-
-
(6,237)
(26,347)
(d) investments
-
-
(e) intellectual property
-
-
(f)
-
-
(c) property, plant and equipment
other non-current assets
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 1
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Consolidated statement of cash flows
2.2
Current quarter
Year to date (12
months)
Proceeds from disposal of:
(a) entities
-
-
(b) businesses
-
-
(c) property, plant and equipment
-
-
(d) investments
-
-
(e) intellectual property
-
-
(f)
-
-
other non-current assets
2.3
Cash flows from loans to other entities
-
-
2.4
Dividends received (see note 3)
-
-
2.5
Other (provide details if material)
(189,882)
(602,123)
2.6
Net cash from / (used in) investing
activities
(196,120)
(628,470)
3.
Cash flows from financing activities
3.1
Proceeds from issues of equity securities
(excluding convertible debt securities)
15,820,208
28,350,213
3.2
Proceeds from issue of convertible debt
securities
-
-
3.3
Proceeds from exercise of options
-
-
3.4
Transaction costs related to issues of
equity securities or convertible debt
securities
(1,177,657)
(1,737,602)
3.5
Proceeds from borrowings
11,488,425
12,224,125
3.6
Repayment of borrowings
(4,297,301)
(11,618,803)
3.7
Transaction costs related to loans and
borrowings
(493,483)
(493,483)
3.8
Dividends paid
-
-
3.9
Other (provide details if material)
-
(14,000)
3.10
Net cash from / (used in) financing
activities
21,340,192
26,710,449
4.
Net increase / (decrease) in cash and
cash equivalents for the period
4.1
Cash and cash equivalents at beginning of
period
201,099
4,415,184
4.2
Net cash from / (used in) operating
activities (item 1.9 above)
(10,811,175)
(19,963,168)
4.3
Net cash from / (used in) investing activities
(item 2.6 above)
(196,120)
(628,470)
4.4
Net cash from / (used in) financing activities
(item 3.10 above)
21,340,192
26,710,449
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 2
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Consolidated statement of cash flows
4.5
Effect of movement in exchange rates on
cash held
4.6
5.
Current quarter
Year to date (12
months)
-
-
Cash and cash equivalents at end of
period
10,533,996
10,533,996
Reconciliation of cash and cash
equivalents
Current quarter
Previous quarter
at the end of the quarter (as shown in the
consolidated statement of cash flows) to the
related items in the accounts
5.1
Bank balances
10,533,996
201,099
5.2
Call deposits
-
-
5.3
Bank overdrafts
-
-
5.4
Other – Trust Account
-
-
5.5
Cash and cash equivalents at end of
quarter (should equal item 4.6 above)
10,533,996
201,099
6.
Payments to related parties of the entity and their
associates
6.1
Aggregate amount of payments to related parties and their
associates included in item 1
789,387
6.2
Aggregate amount of payments to related parties and their
associates included in item 2
Nil
Current quarter
Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an
explanation for, such payments.
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 3
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
7.
Financing facilities
Note: the term “facility’ includes all forms of financing
arrangements available to the entity.
Add notes as necessary for an understanding of the
sources of finance available to the entity.
Total facility
amount at quarter
end
Amount drawn at
quarter end
30,550,000
11,488,425
Nil
Nil
7.1
Loan facilities
7.2
Credit standby arrangements
7.3
Other (please specify)
1,732,500
150,000
7.4
Total financing facilities
32,282,500
11,638,425
7.5
Unused financing facilities available at quarter end
7.6
Include in the box below a description of each facility above, including the lender, interest
rate, maturity date and whether it is secured or unsecured. If any additional financing
facilities have been entered into or are proposed to be entered into after quarter end,
include a note providing details of those facilities as well.
20,644,075
Loan
The loan is from Avenue Venture Opportunity Fund II L.P. For full details, interest rate,
maturity date and security, refer to ASX Announcement dated 17 June 2025.
Other
The Company entered into an At-the-Market Subscription Agreement (“ATM”) (also referred
to as a Controlled Placement Agreement) in November 2018 with Acuity Capital (see
previous announcements on 1 November 2018, 15 February 2019, 30 August 2019, 11
September 2019, 31 July 2020 and 30 January 2023). The ATM provides Recce with up to
$20 million of standby equity capital with an expiry date of 31 January 2026.
To date the Company has utilised the ATM to raise a total of $150,000. The remaining
standby equity capital available under the ATM is currently 4.5m shares which has been
marked to market in this cash flow report as $1,732,500.
There is no guarantee that the Company will be able to execute a utilisation under the
Agreement, which is subject to, for example, market conditions and the prevailing share
price. The Company retains control of all aspects of the placement process. There are no
requirements on the Company to utilise the facility and it may terminate the Agreement at
any time, without cost or penalty.
8.
Estimated cash available for future operating activities
8.1
Net cash from / (used in) operating activities (item 1.9)
(10,811,175)
8.2
Cash and cash equivalents at quarter end (item 4.6)
10,533,996
8.3
Unused finance facilities available at quarter end (item 7.5)
20,644,075
8.4
Total available funding (item 8.2 + item 8.3)
31,178,071
8.5
Estimated quarters of funding available (item 8.4 divided by
item 8.1)
2.88
Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as “N/A”. Otherwise, a
figure for the estimated quarters of funding available must be included in item 8.5.
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 4
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
8.6
If item 8.5 is less than 2 quarters, please provide answers to the following questions:
8.6.1
Does the entity expect that it will continue to have the current level of net operating
cash flows for the time being and, if not, why not?
Answer:
8.6.2
Has the entity taken any steps, or does it propose to take any steps, to raise further
cash to fund its operations and, if so, what are those steps and how likely does it
believe that they will be successful?
Answer:
8.6.3
Does the entity expect to be able to continue its operations and to meet its business
objectives and, if so, on what basis?
Answer:
Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.
Compliance statement
1
This statement has been prepared in accordance with accounting standards and policies
which comply with Listing Rule 19.11A.
2
This statement gives a true and fair view of the matters disclosed.
Date:
31 July 2025
Authorised by: The Board.
(Name of body or officer authorising release – see note 4)
Notes
1.
This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the
entity’s activities for the past quarter, how they have been financed and the effect this has had on its cash position. An
entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is
encouraged to do so.
2.
If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions
in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has been
prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the
corresponding equivalent standard applies to this report.
3.
Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities,
depending on the accounting policy of the entity.
4.
If this report has been authorised for release to the market by your board of directors, you can insert here: “By the board”.
If it has been authorised for release to the market by a committee of your board of directors, you can insert here: “By the
[name of board committee – eg Audit and Risk Committee]”. If it has been authorised for release to the market by a
disclosure committee, you can insert here: “By the Disclosure Committee”.
5.
If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as
complying with recommendation 4.2 of the ASX Corporate Governance Council’s Corporate Governance Principles and
Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial
records of the entity have been properly maintained, that this report complies with the appropriate accounting standards
and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a
sound system of risk management and internal control which is operating effectively.
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 5
Share your feedback
Discover